Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or refractory head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas +1 locations
Conditions: Head and Neck Cancer
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Texas Cancer Care, Fort Worth, Texas +2 locations
Conditions: Breast Cancer
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
Completed
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including patients that have been treated with prior taxane therapy. Overall responses have ranged from 30% to 79%. The major side effects of the combination chemotherapy have been neutropenia, anemia, asthenia, neuropathy, nausea, mucositis, and neutropenic fever
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2007
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Katy, Texas
Conditions: Breast Neoplasms
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
Completed
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033 in combination with paclitaxel and carboplatin in patients with NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2006
Locations: Pfizer Investigational Site, Houston, Texas
Conditions: Carcinoma, Non-Small Cell Lung